Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism

@article{Mannelli2013PalmitoylethanolamideIA,
  title={Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism},
  author={L. di Cesare Mannelli and G. D'Agostino and A. Pacini and R. Russo and M. Zanardelli and C. Ghelardini and A. Calignano},
  journal={Mediators of Inflammation},
  year={2013},
  volume={2013}
}
Neuropathic syndromes which are evoked by lesions to the peripheral or central nervous system are extremely difficult to treat, and available drugs rarely joint an antihyperalgesic with a neurorestorative effect. N-Palmitoylethanolamine (PEA) exerts antinociceptive effects in several animal models and inhibits peripheral inflammation in rodents. Aimed to evaluate the antineuropathic properties of PEA, a damage of the sciatic nerve was induced in mice by chronic constriction injury (CCI) and a… Expand
The neuroprotective effects of micronized PEA (PEA‐m) formulation on diabetic peripheral neuropathy in mice
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 74 REFERENCES
The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice
...
1
2
3
4
5
...